Imatinib for COVID-19: A case report

Alejandro Morales-Ortega, David Bernal-Bello, Cristina Llarena-Barroso, Begoña Frutos-Pérez, Miguel Ángel Duarte-Millán, Vanessa García de Viedma-García, Ana Isabel Farfán-Sedano, Eduardo Canalejo-Castrillero, José Manuel Ruiz-Giardín, Justo Ruiz-Ruiz, Juan Víctor San Martín-López, Alejandro Morales-Ortega, David Bernal-Bello, Cristina Llarena-Barroso, Begoña Frutos-Pérez, Miguel Ángel Duarte-Millán, Vanessa García de Viedma-García, Ana Isabel Farfán-Sedano, Eduardo Canalejo-Castrillero, José Manuel Ruiz-Giardín, Justo Ruiz-Ruiz, Juan Víctor San Martín-López

No abstract available

Keywords: ABL kinase inhibitor; COVID-19; Imatinib; SARS-CoV-2; Treatment.

Conflict of interest statement

Declaration of Competing Interest David Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests.

Figures

Fig. 1
Fig. 1
a Portable chest X-ray showing radiological deterioration with bilateral patchy opacities (March 17, day 11 of symptoms). b Marked improvement of opacities in posteroanterior chest radiograph (April 11, day 20 after discharge and day 36 after the onset of symptoms).

References

    1. World Health Organization (WHO) Novel Coronavirus (2019-nCoV) Situation Report - 51 11 March 2020.
    1. Gasmi A., Noor S., Tippairote T., Dadar M., Menzel A., Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin. Immunol. 2020;215 doi: 10.1016/j.clim.2020.108409.
    1. Bernal-Bello D., Jaenes-Barrios B., Morales-Ortega A., Ruiz-Giardin J.M., García-Bermúdez V., Frutos-Pérez B., Farfán-Sedano A.I., de Ancos-Aracil C., Bermejo F., García-Gil M., Zapatero-Gaviria A., San Martín-López J.V. Imatinib might constitute a treatment option for lung involvement in COVID-19. Autoimmun. Rev. 2020;19 doi: 10.1016/j.autrev.2020.102565.
    1. Rizzo A.N., Sammani S., Esquinca A.E., Jacobson J.R., Garcia J.G., Letsiou E., Dudek S.M. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am. J. Physiol. Cell. Mol. Physiol. 2015;309:1294–1304. doi: 10.1152/ajplung.00031.2015.
    1. Stephens R.S., Johnston L., Servinsky L., Kim B.S., Damarla M. The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. Physiol. Rep. 2015;3 doi: 10.14814/phy2.12589.
    1. Ciarcia R., Vitiello M.T., Galdiero M., Pacilio C.P., Iovane V., d’Angelo D., Pagnini D., Caparrotti G., Conti D., Tomei V., Florio S., Giordano A. Imatinib treatment inhibit IL-6, IL-8, NFKB and AP-1 production and modulate intracellular calcium in CML patients. J. Cell. Physiol. 2012;227:2798–2803. doi: 10.1002/jcp.23029.
    1. Ingraham N.E., Lotfi-Emran S., Thielen B.K., Techar K., Morris R.S., Holtan S.G., Dudley R.A., Tignanelli C.J. Immunomodulation in COVID-19. Lancet Respir. Med. 2020;8:544–546. doi: 10.1016/S2213-2600(20)30226-5.
    1. Felsenstein S., Herbert J.A., McNamara P.S., Hedrich C.M. COVID-19: immunology and treatment options. Clin. Immunol. 2020;215 doi: 10.1016/j.clim.2020.108448.
    1. Coleman C.M., Sisk J.M., Mingo R.M., Nelson E.A., White J.M., Frieman M.B. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J. Virol. 2016;90:8924–8933. doi: 10.1128/JVI.01429-16.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., Zhou H., Hu Z., Zhou W., Zhao L., Chen J., Meng Y., Wang J., Lin Y., Yuan J., Xie Z., Ma J., Liu W.J., Wang D., Xu W., Holmes E.C., Cao G.F., Wu G., Chen W., Shi W., Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren